Addition of Low-dose Interferon Alfa to Nexavar® Does Not Improve Kidney Cancer Outcomes
November 3, 2009 — In a Phase II clinical trial, the combination of low-dose interferon alfa and Nexavar® (sorafenib) did not appear to be any more effective than Nexavar alone for the treatment of metastatic renal cell (kidney) cancer. These results were published in Cancer.
Smoking Cessation Reduces Risk of Head and Neck Cancer
November 3, 2009 — Compared with people who continue to smoke, people who stop smoking have a 30% lower risk of head and neck cancer within one to four years of quitting, and a 77% lower risk after 20 years. Quitting alcohol also reduces the risk of head and neck cancer, but the benefit takes longer to become apparent. These results were published in the International Journal of Epidemiology.
Smoking Cessation Leads to Reduction in Risk of Head and Neck Cancer
November 3, 2009 — Researchers involved in the International Head and Neck Cancer Epidemiology Consortium have reported that smoking cessation for one to four years resulted in a 30% reduction in the risk of head and neck cancer. A benefit of cessation of alcohol drinking, however, was not observed until after 20 years or more. The details of this study appeared in an early online publication in the International Journal of Epidemiology on October 5, 2009.
Select news items provided by Reuters Health